Share ownership Neurizon Therapeutics Limited

NUZ

AU0000357261

Pharmaceuticals

Market Closed - Australian S.E. Other stock markets 11:40:13 17/07/2026 am IST			5-day change	1st Jan Change
0.0630 ^AUD	0.00%		-5.97%	-25.88%

17/07	Neurizon Therapeutics Limited Completes Enrollment In Regimen I Of The Phase 2/3 HEALEY ALS Platform Trial Evaluating NUZ-001 For The Treatment Of Amyotrophic Lateral Sclerosis	CI
12/06	Neurizon Therapeutics Surpasses 50% Dosing Milestone in Trial of ALS Treatment	MT

Share class: Neurizon Therapeutics Limited

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	53,57,89,100	52,02,92,838 ( 97.11 %)	0	97.11 %

Major shareholders: Neurizon Therapeutics Limited

Name	Stocks	%	Valuation
Loon Tan Chek 5.107 %	3,90,00,000	5.107 %	2 M $
Marcus Hughes 1.925 %	1,47,00,943	1.925 %	611 118 $
Michael Thurn 0.3757 %	28,69,276	0.3757 %	119 276 $
Kathryn MacFarlane 0.0351 %	2,67,656	0.0351 %	11 126 $
Sergio Duchini 0.0351 %	2,67,656	0.0351 %	11 126 $

Breakdown by shareholder type

Individuals	7.48%
Unknown	92.52%

Based on 1000 largest holdings

Geographical origin of shareholders

Individuals

7.48%

Based on 1000 largest holdings

Neurizon Therapeutics Limited is an Australia-based clinical-stage biotechnology company. The Company is engaged in advancing treatments for neurodegenerative diseases. It is developing its lead drug candidate, NUZ-001, for the treatment of Amyotrophic Lateral Sclerosis (ALS), which is the common form of motor neurone disease. ALS treatments for patients while exploring the potential of NUZ-001 for broader neurodegenerative applications. ALS is a devastating neurodegenerative condition that primarily affects nerve cells that control voluntary muscles. Through international collaborations and rigorous clinical programs, it is focused on creating new horizons for patients and families impacted by complex neural disorders.

Employees

Sector

Pharmaceuticals

More about the company